Steve Schonfeld’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Steve Schonfeld’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-378,068	Closed	-$593K	–	3234
2022 Q3	$593K	Buy	+378,068	New	+$858K	0.01%	1632

Other funds holding SRNE

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BRF

B. Riley Financial Los Angeles, California $434M AUM 751.56% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Steve Schonfeld's SRNE Position: Q4 2022 in Review

Steve Schonfeld sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2022, closing a stake of 378,068 shares — an estimated $593K sold.

Steve Schonfeld first reported a position in SRNE in Q3 2022 and held it in 1 quarter. The position peaked at $593K in Q3 2022. 223 funds tracked by Wall St. Rank hold SRNE as of Q4 2022.

Steve Schonfeld reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Steve Schonfeld sold 378,068 Sorrento Therapeutics, Inc. shares in Q4 2022, an estimated $593K.
Steve Schonfeld first reported a position in Sorrento Therapeutics, Inc. in Q3 2022 and held it in 1 quarter.
Steve Schonfeld's Sorrento Therapeutics, Inc. position peaked at $593K in Q3 2022.
223 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.